

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

J

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/460,216 12/13/99 ALLAWAY

G 50875-F-PCT-

HM12/1002

COOPER & DUNHAM LLP  
1185 AVENUE OF THE AMERICAS  
NEW YORK NY 10036

EXAMINER

PARKIN, J

ART UNIT	PAPER NUMBER
----------	--------------

1648

DATE MAILED:

10/02/01

J

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks**

## Office Action Summary

Application No. 09/460,216	Applicant(s) Alloway, G., et al.
Examiner Jeffrey S. Parkin, Ph.D.	Art Unit 1648



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

1)  Responsive to communication(s) filed on 12/13/99 + 01/08/01.

2a)  This action is FINAL. 2b)  This action is non-final.

3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

### Disposition of Claims

4)  Claim(s) 61 + 65 is/are pending in the application.

4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5)  Claim(s) \_\_\_\_\_ is/are allowed.

6)  Claim(s) 61 + 65 is/are rejected.

7)  Claim(s) \_\_\_\_\_ is/are objected to.

8)  Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

9)  The specification is objected to by the Examiner.

10)  The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

11)  The proposed drawing correction filed on \_\_\_\_\_ is: a)  approved b)  disapproved.

12)  The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. § 119

13)  Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a)  All b)  Some\* c)  None of:

1.  Certified copies of the priority documents have been received.

2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\*See the attached detailed Office action for a list of the certified copies not received.

14)  Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

### Attachment(s)

15)  Notice of References Cited (PTO-892)

18)  Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_

16)  Notice of Draftsperson's Patent Drawing Review (PTO-948)

19)  Notice of Informal Patent Application (PTO-152)

17)  Information Disclosure Statement(s) (PTO-1449) Paper No(s). 8

20)  Other: \_\_\_\_\_

Serial No.: 09/460,216  
Applicants: Allaway, G., et al.

Docket No.: 50875  
Filing Date: 12/13/99

### Detailed Office Action

#### *Status of the Claims*

1. Acknowledgement is hereby made of the preliminary amendments filed 13 December, 1999, 26 April, 2000, and 08 January, 2001, wherein claims 1-60 and 62-64 were canceled without prejudice or disclaimer, claim 61 amended, and new claim 65 introduced. Claims 5 61 and 65 are pending in the instant application.

#### *Petition to Correct Inventorship*

##### *Pursuant to 37 C.F.R. § 1.48*

2. In view of the papers filed 08 January, 2001, in response to the cancellation of claims during prosecution, wherein one or more of the currently named inventors was no longer an inventor of at least one claim remaining in the application, this application has been corrected in compliance with 37 C.F.R. § 1.48(b). The inventorship of this application has been changed by deleting William C. Olson 15 as an inventor.

#### *Information Disclosure Statement*

3. The information disclosure statement filed 23 January, 2001, has been placed in the application file and the information referred to 20 therein has been considered.

#### *35 U.S.C. § 112, First Paragraph*

4. The following is a quotation of the first paragraph of 35 U.S.C. § 112:

25       The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

30       5. Claims 61 and 65 are rejected under 35 U.S.C. § 112, first

paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims are broadly directed toward a method for inhibiting HIV-1 infection of CD4<sup>+</sup> cells through the administration of a non-peptidyl inhibitory agent that is capable of binding to a chemokine coreceptor required for viral entry. The claims further stipulate that the agent of interest cannot be a bicyclam or derivative thereof.

The legal considerations that govern enablement determinations pertaining to undue experimentation are disclosed in *In re Wands*, 8 U.S.P.Q.2d 1400 (C.A.F.C. 1988) and *Ex parte Forman* 230 U.S.P.Q. 546 (PTO Bd. Pat. App. Int., 1986). The courts concluded that several factual inquiries should be considered when making such assessments including the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims. *In re Rainer*, 52 C.C.P.A. 1593, 347 F.2d 574, 146 U.S.P.Q. 218 (1965). The disclosure fails to provide adequate guidance pertaining to a number of these considerations as follows:

1) The disclosure fails to provide any guidance pertaining to the structural requirements of any given non-peptidyl inhibitor that is not a bicyclam or derivative thereof. The disclosure fails to teach which chemical structures are critical for binding to any given chemokine coreceptor and which structures are critical for the antiviral activity. The disclosure fails to identify any parent compounds, or derivatives thereof, that can reasonably be expected to function in the desired manner. Thus, the skilled artisan has been extended an undue invitation to further experimentation to try to identify putative antiviral agents and

determine their structures.

2) The disclosure fails to provide sufficient guidance pertaining to the molecular determinants modulating HIV-1 envelope/coreceptor/antiviral binding interactions. In order to 5 rationally design a putative therapeutic, the skilled artisan would need a knowledge of those portions of CCR5 or CXCR4 that should be targets of any given antiviral. However, the specification is silent pertaining to this concern and fails to identify any critical regions of the chemokine coreceptors that should be the 10 targets of antiviral development.

3) The disclosure fails to provide any working embodiments that meet the claimed limitations. While it is noted that the disclosure describes the identification of a putative antiviral agent (e.g., JM3100), nevertheless, this compound is a bycyclam agent and does 15 not fall within the claimed limitations. There are no other examples involving non-peptidyl agents provided in the disclosure.

4) The claims are of excessive breadth and encompass any given putative antiviral agent without providing any meaningful structural limitations concerning that agent. The disclosure 20 simply fails to support such breadth in the claim language.

5) The prior art describes a number of concerns pertaining to the development of fusion inhibitors. First, it is well-known that the chemokine family includes a large number of proteins that share limited genetic relatedness (~ 20%) (Proudfoot et al., 1999; 25 Proudfoot et al., 2000). Thus, it appears unlikely that any given inhibitor will have a broad range of activity, particularly in the absence of the identification of any critical molecular determinants that are shared by all members of the family. Second, even if a putative antiviral compound was identified, there are a 30 number of important immunological and therapeutic concerns that need to be considered (Berger et al., 1999). For instance, will the loss of normal chemokine receptor function of a specific coreceptor

be tolerated and accepted in the host? Will the impairment of CCR5 coreceptor usage accelerate disease progression by enhancing the selection for CXCR4 coreceptor usage? Do multiple members of the coreceptor repertoire need to be blocked in order to achieve a therapeutic effect? The disclosure is silent pertaining to these concerns.

5           6) The prior art (Öberg and Vrang, 1990; Yarchoan and Broder, 1992; Gait and Karn, 1995; Flexner and Hendrix, 1997) also provides a number of generic concerns pertaining to the development of any 10 given putative antiviral compound to inhibit HIV-1 infection. It has been well-documented in the prior art that the development of suitable HIV-1 therapeutics has been a long and arduous process, often ending in failure. This is due to a number of considerations such as a failure to understand the molecular determinants 15 modulating many viral protein and host cell factor interactions, the failure of *in vitro* tissue culture studies and *in vivo* animal models to adequately predict clinical efficacy, the failure of many compounds to have acceptable pharmacological profiles, despite initial favorable *in vitro* and *in vivo* activities, and the failure 20 of related structural analogs to function in the desired manner, which provides further evidence of the specificity of these molecular interactions. The difficulties associated with developing efficacious anti-HIV-1 agents are best summarized by Gait and Karn (1995) who state (see Conclusions, p. 37):

25           There can be few tasks in biotechnology that are more challenging than designing antiviral drugs. All of the protease inhibitors that have entered into clinical trials are potent inhibitors of HIV-1 replication in cell culture, and exhibit remarkable selectivities for the viral enzyme. 30 Unfortunately, early protease inhibitors tended to suffer from problems of short serum half-life, poor availability and rapid clearance. As these pharmacokinetic problems have been addressed and solved, new difficulties have emerged from the resultant clinical experience, such as sequestration of the drug by serum proteins, drug resistance and uneven 35 distribution throughout the body. Since these types of

problems are unpredictable, it remains necessary to take into account the pharmacological parameters in any drug development programme at the earliest possible stage.

- 5 The disclosure fails to provide any guidance pertaining to these caveats. Accordingly, when all the aforementioned factors are considered *in toto*, it would clearly require undue experimentation from the skilled artisan to practice the claimed invention.

10

**35 U.S.C. § 120**

15

6. Applicants' claim for domestic priority under 35 U.S.C. § 119(e) and 120 is acknowledged. However, the applications upon which priority is claimed fail to provide adequate support under 35 U.S.C. § 112 for claims 61 and 65 of this application. These earlier applications relied upon fail to provide adequate support for non-peptidyl inhibitory agents that are not of the bicylam family. Accordingly, for the purposes of applying prior art, the effective filing date of the instant application will be 12 December, 1998.

20

**35 U.S.C. § 102**

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

25

A person shall be entitled to a patent unless --

30

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

35

8. Claims 61 and 65 are rejected under 35 U.S.C. § 102(a) as being anticipated by Howard et al. (1998). This teaching describes a method for inhibiting HIV-1 infection of CD4<sup>+</sup> cells through the administration of a non-peptidyl agent (e.g., NSC 651016, a distamycin analog) that binds to a chemokine receptor (e.g., CCR5,

CXCR4) and is not a bicyclam or a derivative thereof (see Results, pp. 8-10). This teaching clearly meets all of the claimed limitations.

5

### **Correspondence**

9. The Art Unit location of your application in the Patent and Trademark Office has changed. To facilitate the correlation of related papers and documents for this application, all future correspondence should be directed to **art unit 1648**.

10

10. Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703) 308-4242 or (703) 305-3014. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 308-4426. Applicants are encouraged to notify the Examiner prior to the submission of such documents to facilitate their expeditious processing and entry.

15

11. Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (703) 308-2227. The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisors, James Housel or Laurie Scheiner, can be reached at (703) 308-4027 or (703) 308-1122, respectively. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

20

30

Respectfully,

Jeffrey S. Parkin, Ph.D.  
Patent Examiner  
Art Unit 1648

26 September, 2001